Concepts (289)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Cord Injuries | 14 | 2022 | 551 | 1.450 |
Why?
|
| Spinal Cord Compression | 2 | 2021 | 23 | 1.140 |
Why?
|
| Decompression, Surgical | 2 | 2021 | 55 | 0.880 |
Why?
|
| Anorectal Malformations | 1 | 2022 | 2 | 0.860 |
Why?
|
| Digestive System Abnormalities | 1 | 2022 | 7 | 0.850 |
Why?
|
| Meningitis | 1 | 2022 | 23 | 0.840 |
Why?
|
| Spinal Diseases | 1 | 2022 | 53 | 0.820 |
Why?
|
| Syringomyelia | 1 | 2021 | 4 | 0.760 |
Why?
|
| Laminectomy | 1 | 2021 | 13 | 0.750 |
Why?
|
| Thoracic Vertebrae | 1 | 2021 | 52 | 0.730 |
Why?
|
| Sciatica | 1 | 2018 | 4 | 0.640 |
Why?
|
| Hemangioblastoma | 1 | 2018 | 6 | 0.630 |
Why?
|
| Varicose Veins | 1 | 2018 | 11 | 0.630 |
Why?
|
| Nerve Compression Syndromes | 1 | 2018 | 16 | 0.630 |
Why?
|
| Estradiol | 6 | 2022 | 176 | 0.620 |
Why?
|
| Glioblastoma | 5 | 2020 | 219 | 0.580 |
Why?
|
| Glioma | 3 | 2007 | 140 | 0.570 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2016 | 2 | 0.540 |
Why?
|
| Radial Neuropathy | 1 | 2016 | 2 | 0.540 |
Why?
|
| Brain Neoplasms | 5 | 2020 | 371 | 0.520 |
Why?
|
| Estrogens | 7 | 2022 | 173 | 0.490 |
Why?
|
| Recovery of Function | 7 | 2022 | 506 | 0.480 |
Why?
|
| Motor Neurons | 5 | 2012 | 98 | 0.440 |
Why?
|
| Meningocele | 1 | 2012 | 12 | 0.410 |
Why?
|
| Quadriplegia | 1 | 2012 | 29 | 0.410 |
Why?
|
| Esophageal Stenosis | 1 | 2012 | 36 | 0.400 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2012 | 33 | 0.400 |
Why?
|
| Osteomyelitis | 1 | 2012 | 40 | 0.390 |
Why?
|
| Cervical Vertebrae | 1 | 2012 | 86 | 0.380 |
Why?
|
| Apoptosis | 11 | 2020 | 1641 | 0.360 |
Why?
|
| Photochemotherapy | 2 | 2007 | 59 | 0.350 |
Why?
|
| Palliative Care | 1 | 2012 | 271 | 0.340 |
Why?
|
| Dihematoporphyrin Ether | 1 | 2007 | 3 | 0.300 |
Why?
|
| Supratentorial Neoplasms | 1 | 2007 | 4 | 0.300 |
Why?
|
| Cranial Nerve Diseases | 1 | 2007 | 14 | 0.300 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 37 | 0.300 |
Why?
|
| Spinal Cord | 5 | 2022 | 244 | 0.290 |
Why?
|
| Stents | 1 | 2012 | 657 | 0.290 |
Why?
|
| Meningioma | 2 | 2020 | 54 | 0.290 |
Why?
|
| Nanoparticles | 3 | 2020 | 254 | 0.290 |
Why?
|
| Glomus Jugulare Tumor | 1 | 2006 | 4 | 0.280 |
Why?
|
| Brain Injuries | 1 | 2010 | 268 | 0.280 |
Why?
|
| Immunotoxins | 1 | 2006 | 23 | 0.270 |
Why?
|
| Radioisotopes | 1 | 2006 | 40 | 0.270 |
Why?
|
| Allyl Compounds | 2 | 2018 | 29 | 0.270 |
Why?
|
| Sulfides | 2 | 2018 | 43 | 0.270 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2018 | 116 | 0.260 |
Why?
|
| Humans | 23 | 2022 | 68618 | 0.260 |
Why?
|
| Histone Deacetylases | 2 | 2018 | 99 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 2223 | 0.250 |
Why?
|
| Postoperative Complications | 1 | 2012 | 1615 | 0.230 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2021 | 333 | 0.220 |
Why?
|
| Male | 17 | 2022 | 37321 | 0.220 |
Why?
|
| Drug Delivery Systems | 3 | 2017 | 236 | 0.220 |
Why?
|
| Aged | 7 | 2022 | 14862 | 0.210 |
Why?
|
| Sacrum | 1 | 2022 | 14 | 0.210 |
Why?
|
| Disease Models, Animal | 7 | 2022 | 2550 | 0.210 |
Why?
|
| Anal Canal | 1 | 2022 | 28 | 0.210 |
Why?
|
| Animals | 20 | 2022 | 20881 | 0.210 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2022 | 12 | 0.200 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2022 | 2083 | 0.190 |
Why?
|
| Receptors, Melatonin | 2 | 2012 | 8 | 0.190 |
Why?
|
| Rats | 11 | 2022 | 5300 | 0.190 |
Why?
|
| Lipomatosis | 1 | 2021 | 4 | 0.190 |
Why?
|
| Epidural Space | 1 | 2021 | 15 | 0.190 |
Why?
|
| Neuroprotective Agents | 6 | 2016 | 317 | 0.190 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 102 | 0.190 |
Why?
|
| Neurofibromin 2 | 1 | 2020 | 10 | 0.180 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 14 | 0.180 |
Why?
|
| Gliosis | 2 | 2020 | 51 | 0.180 |
Why?
|
| Adult | 7 | 2022 | 21403 | 0.180 |
Why?
|
| Locomotion | 2 | 2022 | 135 | 0.170 |
Why?
|
| Quinolones | 1 | 2020 | 60 | 0.170 |
Why?
|
| Adipose Tissue | 1 | 2021 | 221 | 0.170 |
Why?
|
| Inflammation | 5 | 2022 | 1030 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 101 | 0.170 |
Why?
|
| Female | 9 | 2021 | 38074 | 0.170 |
Why?
|
| Benzimidazoles | 1 | 2020 | 128 | 0.170 |
Why?
|
| Sciatic Nerve | 1 | 2018 | 26 | 0.160 |
Why?
|
| Birds | 1 | 2018 | 17 | 0.160 |
Why?
|
| Nerve Regeneration | 2 | 2020 | 42 | 0.150 |
Why?
|
| Glutamic Acid | 2 | 2012 | 332 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 4848 | 0.150 |
Why?
|
| Cell Line, Tumor | 6 | 2020 | 1851 | 0.150 |
Why?
|
| Drug Liberation | 1 | 2017 | 17 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 626 | 0.150 |
Why?
|
| Lumbar Vertebrae | 1 | 2018 | 112 | 0.150 |
Why?
|
| Drug Carriers | 1 | 2017 | 90 | 0.140 |
Why?
|
| Reoperation | 1 | 2018 | 467 | 0.140 |
Why?
|
| Child | 2 | 2022 | 6405 | 0.140 |
Why?
|
| Middle Aged | 7 | 2012 | 21147 | 0.140 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2016 | 15 | 0.140 |
Why?
|
| Gamma Rays | 1 | 2015 | 64 | 0.130 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 30 | 0.130 |
Why?
|
| Limonins | 1 | 2015 | 10 | 0.130 |
Why?
|
| Catechols | 1 | 2015 | 14 | 0.130 |
Why?
|
| Flavones | 1 | 2015 | 11 | 0.130 |
Why?
|
| Lanosterol | 1 | 2015 | 11 | 0.130 |
Why?
|
| Fatty Alcohols | 1 | 2015 | 14 | 0.130 |
Why?
|
| Heptanoic Acids | 1 | 2015 | 28 | 0.120 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 41 | 0.120 |
Why?
|
| Necrosis | 1 | 2015 | 239 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2015 | 97 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1140 | 0.120 |
Why?
|
| Triterpenes | 1 | 2015 | 40 | 0.120 |
Why?
|
| Nerve Degeneration | 2 | 2014 | 134 | 0.120 |
Why?
|
| Neurons | 2 | 2018 | 881 | 0.110 |
Why?
|
| Contusions | 1 | 2013 | 11 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 163 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 234 | 0.110 |
Why?
|
| Microglia | 2 | 2011 | 143 | 0.110 |
Why?
|
| Injury Severity Score | 2 | 2011 | 204 | 0.110 |
Why?
|
| Cervical Atlas | 1 | 2012 | 3 | 0.110 |
Why?
|
| Vertebroplasty | 1 | 2012 | 16 | 0.100 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2012 | 8 | 0.100 |
Why?
|
| Logistic Models | 3 | 2011 | 1420 | 0.100 |
Why?
|
| Interferon-gamma | 2 | 2011 | 241 | 0.100 |
Why?
|
| Cephalosporins | 1 | 2012 | 59 | 0.100 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2012 | 52 | 0.100 |
Why?
|
| Vancomycin | 1 | 2012 | 60 | 0.100 |
Why?
|
| Genistein | 1 | 2011 | 26 | 0.100 |
Why?
|
| Biocompatible Materials | 1 | 2013 | 247 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 304 | 0.090 |
Why?
|
| Orthopedic Procedures | 1 | 2012 | 102 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 3 | 2020 | 111 | 0.090 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 142 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2011 | 117 | 0.090 |
Why?
|
| Melatonin | 1 | 2010 | 39 | 0.090 |
Why?
|
| Light | 2 | 2007 | 152 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2020 | 223 | 0.080 |
Why?
|
| Prognosis | 2 | 2014 | 2093 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 848 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 108 | 0.080 |
Why?
|
| Trauma Centers | 1 | 2010 | 197 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1851 | 0.080 |
Why?
|
| Deglutition Disorders | 1 | 2012 | 297 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2011 | 7277 | 0.080 |
Why?
|
| Cranial Fossa, Middle | 1 | 2007 | 8 | 0.080 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2007 | 7 | 0.080 |
Why?
|
| Facial Nerve Diseases | 1 | 2007 | 13 | 0.080 |
Why?
|
| Trigeminal Nerve | 1 | 2007 | 22 | 0.080 |
Why?
|
| Facial Nerve | 1 | 2007 | 25 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2010 | 880 | 0.070 |
Why?
|
| Cell Death | 3 | 2016 | 329 | 0.070 |
Why?
|
| Brain | 1 | 2018 | 2176 | 0.070 |
Why?
|
| Photic Stimulation | 1 | 2007 | 229 | 0.070 |
Why?
|
| Benzamides | 2 | 2020 | 156 | 0.070 |
Why?
|
| Temporal Lobe | 1 | 2007 | 125 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 629 | 0.070 |
Why?
|
| Sex Factors | 1 | 2010 | 1266 | 0.070 |
Why?
|
| Infusion Pumps | 1 | 2006 | 39 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2007 | 275 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2018 | 238 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2010 | 718 | 0.060 |
Why?
|
| Blood-Brain Barrier | 1 | 2006 | 99 | 0.060 |
Why?
|
| Signal Transduction | 4 | 2020 | 2689 | 0.060 |
Why?
|
| Age Factors | 1 | 2010 | 1864 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 1026 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2020 | 331 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1174 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2010 | 2007 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 951 | 0.060 |
Why?
|
| Carcinoma | 1 | 2005 | 215 | 0.060 |
Why?
|
| Infant | 1 | 2010 | 2891 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2005 | 201 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2010 | 3187 | 0.050 |
Why?
|
| Risk Factors | 2 | 2010 | 5731 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 756 | 0.050 |
Why?
|
| Neurosurgical Procedures | 1 | 2004 | 98 | 0.050 |
Why?
|
| Neuroprotection | 1 | 2022 | 28 | 0.050 |
Why?
|
| Receptor, Melatonin, MT1 | 2 | 2012 | 10 | 0.050 |
Why?
|
| Receptor, Melatonin, MT2 | 2 | 2012 | 11 | 0.050 |
Why?
|
| Parenchymal Tissue | 1 | 2020 | 4 | 0.050 |
Why?
|
| Axons | 1 | 2022 | 139 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2015 | 954 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2011 | 2673 | 0.050 |
Why?
|
| DNA Modification Methylases | 1 | 2020 | 24 | 0.050 |
Why?
|
| United States | 1 | 2013 | 7367 | 0.050 |
Why?
|
| Sulfones | 1 | 2020 | 45 | 0.050 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2020 | 22 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2020 | 36 | 0.050 |
Why?
|
| DNA Repair Enzymes | 1 | 2020 | 53 | 0.040 |
Why?
|
| Adolescent | 2 | 2010 | 8912 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 57 | 0.040 |
Why?
|
| Triazines | 1 | 2020 | 48 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 1070 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2011 | 174 | 0.040 |
Why?
|
| Imidazoles | 1 | 2020 | 175 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2020 | 233 | 0.040 |
Why?
|
| Mice | 4 | 2013 | 8474 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 194 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 178 | 0.040 |
Why?
|
| Cytokines | 2 | 2015 | 866 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2013 | 1040 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 546 | 0.040 |
Why?
|
| Motor Activity | 1 | 2022 | 621 | 0.040 |
Why?
|
| Cell Survival | 2 | 2012 | 901 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 332 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 800 | 0.040 |
Why?
|
| Biomarkers | 2 | 2015 | 1593 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 331 | 0.040 |
Why?
|
| Albumins | 1 | 2017 | 72 | 0.040 |
Why?
|
| Cell Line | 2 | 2012 | 1752 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2017 | 85 | 0.040 |
Why?
|
| Solutions | 1 | 2017 | 115 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2010 | 1200 | 0.040 |
Why?
|
| Liposomes | 1 | 2017 | 107 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2017 | 150 | 0.040 |
Why?
|
| Water | 1 | 2017 | 230 | 0.030 |
Why?
|
| Astrocytes | 1 | 2018 | 270 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 1047 | 0.030 |
Why?
|
| Lipids | 1 | 2017 | 298 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 196 | 0.030 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2015 | 15 | 0.030 |
Why?
|
| Polymers | 1 | 2017 | 244 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 194 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 57 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 2015 | 85 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 64 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 1213 | 0.030 |
Why?
|
| Aminolevulinic Acid | 2 | 2005 | 5 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2006 | 7029 | 0.030 |
Why?
|
| Chemokines | 1 | 2015 | 119 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 57 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1745 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 84 | 0.030 |
Why?
|
| Photosensitizing Agents | 2 | 2005 | 32 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2015 | 152 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 852 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2015 | 222 | 0.030 |
Why?
|
| Rabbits | 2 | 2005 | 509 | 0.030 |
Why?
|
| South Carolina | 2 | 2011 | 2752 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 160 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 100 | 0.030 |
Why?
|
| Calbindins | 1 | 2012 | 23 | 0.030 |
Why?
|
| Spinal Neoplasms | 1 | 2012 | 14 | 0.030 |
Why?
|
| Carcinoid Tumor | 1 | 2012 | 20 | 0.030 |
Why?
|
| Intestinal Neoplasms | 1 | 2012 | 30 | 0.030 |
Why?
|
| Parvalbumins | 1 | 2012 | 29 | 0.030 |
Why?
|
| Bone Cements | 1 | 2012 | 39 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 508 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 196 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2011 | 31 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2011 | 75 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2016 | 1330 | 0.020 |
Why?
|
| Hybrid Cells | 1 | 2010 | 18 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2011 | 200 | 0.020 |
Why?
|
| Cell Fusion | 1 | 2010 | 23 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 167 | 0.020 |
Why?
|
| Calcium Channels, L-Type | 1 | 2010 | 34 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2011 | 99 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2011 | 99 | 0.020 |
Why?
|
| Nitriles | 1 | 2010 | 68 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 434 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 392 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 290 | 0.020 |
Why?
|
| Phenols | 1 | 2010 | 73 | 0.020 |
Why?
|
| Tryptamines | 1 | 2010 | 7 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 176 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2010 | 22 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2010 | 40 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 592 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 658 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 175 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2010 | 109 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1038 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2010 | 93 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 791 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2010 | 190 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 168 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2009 | 85 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 499 | 0.020 |
Why?
|
| Length of Stay | 1 | 2011 | 780 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 1118 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1603 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2009 | 285 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 581 | 0.020 |
Why?
|
| Mitochondria | 1 | 2011 | 643 | 0.020 |
Why?
|
| Calcium | 1 | 2010 | 929 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 261 | 0.010 |
Why?
|
| Protoporphyrins | 1 | 2004 | 10 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2004 | 33 | 0.010 |
Why?
|
| Microscopy | 1 | 2004 | 64 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2004 | 112 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 652 | 0.010 |
Why?
|
| Models, Animal | 1 | 2004 | 252 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2005 | 419 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2324 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 689 | 0.010 |
Why?
|